Biopharmaceutical company Sirnaomics has initiated the Phase IIa trial of its small interfering RNA (siRNA) therapeutic candidate STP705 (Cotsiranib) to treat patients with hypertrophic scar.

STP705 is an anti-fibrosis siRNA therapeutic designed to reduce fibrotic and inflammatory activity with dual-targeted inhibition and polypeptide nanoparticle (PNP)-enhanced delivery.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug is made of two siRNA oligonucleotides, which target TGF-β1 and COX-2 mRNAs, as well as contain nanoparticles with Histidine-Lysine Co-Polymer (HKP) peptide.

The randomised, double-blind, placebo controlled Phase IIa trial will evaluate the safety and efficacy of different doses of intradermal STP705 injection in patients with hypertrophic scar.

"The study will initially assess the safety, tolerability, and efficacy of the drug for treatment of skin hypertrophic scars caused due to abnormal healing after surgical procedures."

Sirnaomics founder and chief executive officer Patrick Lu said: "This first-in-man study of STP705 in the US will provide safety and efficacy evidence of Sirnaomics' unique siRNA drug design and the PNP formulation for a novel antifibrotic therapeutic approach.

"The knowledge and experience from the intradermal injection of this siRNA therapeutic should pave a path towards utilising this drug candidate systemically for other fibrotic disease treatments, addressing broader unmet clinical needs."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The hypertrophic scar is formed during burn and traumatic injuries and surgical procedures, and also causes pain, pruritus and contractures. It features TGF-β1 as a regulator of the aberrant fibrogenic response and COX-2 as a potent proinflammatory and proliferative mediator.

The study will initially assess the safety, tolerability, and efficacy of the drug for treatment of skin hypertrophic scars caused due to abnormal healing after surgical procedures.

The trial will further utilise validated scar assessment tools to measure the patient and physician reported scar outcomes.